Drug Profile
Research programme: dopamine D3 receptor antagonists - AbbVie
Alternative Names: A-690344; A-767119; A-932156; ABT-127; Tetracyclic spirobenzazepine dopamine antagonists - Abbott LaboratoriesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class Benzazepines; Small molecules
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Behavioural disorders; Schizophrenia; Substance-related disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Behavioural-disorders in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in Germany (Intraperitoneal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in Germany (PO)